Ian Pyrah work email
- Valid
- Valid
- Valid
- Valid
Ian Pyrah personal email
Ian Pyrah phone numbers
International Biopharma Business and Scientific Leader with over 20 years experience in top tier companies. Experienced with proven success across diverse therapeutic areas and all stages of drug discovery and development from target validation, animal model interpretation, biomarker development, IND submission, NDA/BLA submission, FDA advisory committee sponsor presenter, through post marketing assessment. International scientific thought leader within the toxicology community and regulatory authorities. Strong track record of recruiting and developing top talent. Trained and experienced in broad business skills, successfully initiating and leading cross-functional teams to deliver multimillion dollar savings and improved business efficiency. Balanced individual with strong ethics and community involvement.
-
Svp Non-Clinical DevelopmentKailera Therapeutics Dec 2024 - PresentBuilding a Non-Clinical Development group to support development of a broad portfolio of incretin therapeutics. -
Svp Translational SciencesImmunome, Inc. Mar 2024 - Dec 2024Bothell, Washington, UsBuilt a Translational Sciences team from the ground up to support a portfolio of Antibody Drug Conjugates and Radioligand Therapies. Review and assessment of multiple in license opportunities. Support outbound business development. -
Chief Scientific OfficerStealth Biotech Startup Oct 2023 - Mar 2024
-
Chief Development OfficerStealth Biotech Startup Mar 2021 - Oct 2023Responsible for all Research and Development activities including scientific oversight of basic research, development and implementation of biomarkers, review of non-clinical safety, and design, conduct and analysis of FIH studies
-
Senior Vice President Translational SciencesSeattle Genetics Mar 2020 - Mar 2021Bothell, Washington, Us -
Vice President Translational SciencesSeattle Genetics Oct 2017 - Mar 2020Bothell, Washington, UsLeading Translational Sciences which includes non-clinical sciences, in vivo research, experimental pharmacology, clinical pharmacology, bioinformatics and biomarker development.
-
Vice President Non-Clinical SciencesSeattle Genetics Jun 2016 - Oct 2017Bothell, Washington, Us
-
Preclinical Executive DirectorAmgen 2006 - 2016Thousand Oaks, Ca, UsLeadership accountability for delivery of the late stage portfolio including direct accountability for toxicology project input and responsibility for cross functional integration of all data for recent successful submissions including Prolia, Xgeva, Blincyto, Corlanor, Repatha, Neupogen/Neulasta, Imlygic. Successful in recruiting, developing, and mentoring scientific and operational staff including a wide range of grade levels.Leadership accountability for cross functional supply chain and logistic project with annual budget in excess of $140M with direct accountability to R&D SVPs which required forming and leading a team of senior executives from operations, finance, global sourcing, and R&D to successfully develop a vision and drive strategy against that vision. Successful in achieving multi-million dollar annual savings and major service improvement.Leadership accountability for major change initiative “Amgen Full Potential” in discovery research and translational sciences – working cross functionally to develop a flexible and responsive business model and drive change. Accountability to board level staff. Initiative delivering multimillion dollar annual savings and improving speed to market.Prominent in the external scientific and business community including Member of the Expert Working Groups for revision of ICH S1 (Rodent Carcinogenicity Studies for Human Pharmaceuticals) and ICH S9 (Nonclinical Evaluation for Anticancer Pharmaceuticals) Question & Answer; Member of the Preclinical Development Committee of EFPIA (European Federation of Pharmaceutical Industries and Associations); Member Board of Directors UCLA Anderson Business School -
Principal PathologistAstrazeneca 2002 - 2006Cambridge, Cambridgeshire, GbI was a toxicologic pathologist, toxicology project representative, and managed a pathology special techniques lab including validation of human tissue biomarkers. -
DirectorGlaxosmithkline 1999 - 2002Brentford, Middlesex, GbI lead the Nonclinical Evaluation of Novel Therapeutics for the neurology Centre of Excellence for Drug Discovery
Ian Pyrah Skills
Ian Pyrah Education Details
-
Ucla Anderson School Of ManagementGeneral -
National University Of SingaporeGeneral
-
The University Of EdinburghVeterinary Pathology And Pathobiology
-
The University Of EdinburghVeterinary Science
Frequently Asked Questions about Ian Pyrah
What company does Ian Pyrah work for?
Ian Pyrah works for Kailera Therapeutics
What is Ian Pyrah's role at the current company?
Ian Pyrah's current role is SVP Non-Clinical Development.
What is Ian Pyrah's email address?
Ian Pyrah's email address is ip****@****gen.com
What is Ian Pyrah's direct phone number?
Ian Pyrah's direct phone number is (805) 447*****
What schools did Ian Pyrah attend?
Ian Pyrah attended Ucla Anderson School Of Management, National University Of Singapore, The University Of Edinburgh, The University Of Edinburgh.
What are some of Ian Pyrah's interests?
Ian Pyrah has interest in Health.
What skills is Ian Pyrah known for?
Ian Pyrah has skills like Drug Discovery, Toxicology, Pathology, Drug Development, Biomarkers, Regulatory Affairs, Validation, Cro, Biomarker Discovery, Business Strategy, Oncology, Glp.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial